CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.07B, above the global median of $1.18B
- PositionReturn on equity is 38%, higher than 95% of its Biotechnology peers (median -23.6%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
34.07BCNY5.07B · vs all stocks (USD)
Trailing P/E
66.51xvs Biotechnology peers
Revenue (TTM)
1.64BCNY243.92M · vs all stocks (USD)
Profit Margin
33.52%vs Biotechnology peers
Beta
-0.1070xvs all stocks
52-Week Change
17.97%vs all stocks
Market Capitalization
34.07BCNY5.07B · vs all stocks (USD)
Enterprise Value
30.78BCNY4.58B · vs all stocks (USD)
Trailing P/E
66.51xvs Biotechnology peers
Price to Sales (TTM)
22.33xvs Biotechnology peers
Price to Book (MRQ)
21.28xvs Biotechnology peers
Enterprise to Revenue
18.77xvs Biotechnology peers
Enterprise to EBITDA
62.02xvs Biotechnology peers
Gross Margin
87.48%vs Biotechnology peers
Profit Margin
33.52%vs Biotechnology peers
Operating Margin
-6.54%vs Biotechnology peers
Return on Assets (TTM)
8.80%vs Biotechnology peers
Return on Equity (TTM)
38.00%vs Biotechnology peers
Revenue (TTM)
1.64BCNY243.92M · vs all stocks (USD)
Revenue per Share (TTM)
6.19CNYUpdated Aug 21, 2026Quarterly Revenue Growth
44.20%vs Biotechnology peers
Gross Profit (TTM)
1.53BCNY227.60M · vs all stocks (USD)
EBITDA (TTM)
496.32MCNY73.81M · vs all stocks (USD)
Net Income (TTM)
549.87MCNY81.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
78.95%vs Biotechnology peers
Operating Cash Flow (TTM)
796.75MCNY118.49M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
191.14MCNY28.43M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
810.48MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
77.63MCNYFY2025 · Dec 31, 2025Gross Profit
732.85MCNYFY2025 · Dec 31, 2025Operating Income
-195.38MCNY-29.05M · vs all stocks (USD)
Pre-tax Income
-168.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
-3.53MCNYFY2025 · Dec 31, 2025Net Income
-165.13MCNYFY2025 · Dec 31, 2025EBIT
-144.45MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.84MCNYFY2025 · Dec 31, 2025Research & Development
429.91MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
337.73MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.39MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
55.12MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
24.20MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-165.13MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.18MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-207.92MCNYFY2025 · Dec 31, 2025Free Cash Flow
-389.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
124.66MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-165.13MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-24.00MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-24.40MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
5.60MCNYFY2025 · Dec 31, 2025Capital Expenditures
-181.47MCNYFY2025 · Dec 31, 2025Sale of Investments
125.83MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-55.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.13BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.01BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-26.09MCNYFY2025 · Dec 31, 2025Other Financing Charges
-98.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-7.50MCNYFY2025 · Dec 31, 2025Shares Outstanding
264.71MSharesUpdated Aug 21, 2026Float Shares
167.35MSharesUpdated Aug 21, 2026% Held by Insiders
29.61%vs all stocks
% Held by Institutions
28.55%vs all stocks
Total Cash (MRQ)
2.47BCNY367.27M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.33CNYUpdated Aug 21, 2026Total Debt (MRQ)
812.94MCNY120.89M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4725xvs Biotechnology peers
Current Ratio (MRQ)
2.50xvs Biotechnology peers
Book Value per Share (MRQ)
6.50CNYUpdated Aug 21, 2026Total Assets
2.97BCNY441.55M · vs all stocks (USD)
Total Current Assets
2.44BCNYFY2025 · Dec 31, 2025Total Liabilities
1.89BCNYFY2025 · Dec 31, 2025Total Non-current Assets
526.08MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
460.80MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.43BCNYFY2025 · Dec 31, 2025Cash
1.91BCNYFY2025 · Dec 31, 2025Cash Equivalents
124.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.03BCNYFY2025 · Dec 31, 2025Accounts Receivable
151.22MCNYFY2025 · Dec 31, 2025Inventory
173.27MCNYFY2025 · Dec 31, 2025Accounts Payable
244.16MCNYFY2025 · Dec 31, 2025Short-term Debt
1.04BCNYFY2025 · Dec 31, 2025Other Current Liabilities
408.91KCNYFY2025 · Dec 31, 2025Long-term Debt
92.60MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
358.49MCNYFY2025 · Dec 31, 2025Common Stock (Book)
264.71MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.28BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.08BCNY160.67M · vs all stocks (USD)
52-Week Low
75.10CNYUpdated Aug 21, 202652-Week High
160.00CNYUpdated Aug 21, 202652-Week Change
17.97%vs all stocks
Beta
-0.1070xvs all stocks
50-Day MA
120.19CNYUpdated Aug 21, 2026200-Day MA
102.29CNYUpdated Aug 21, 2026Avg 10-Day Volume
8.15MSharesUpdated Aug 21, 2026Avg 30-Day Volume
8.64MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
2.08CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 38%, higher than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: 0.38Industry median: -0.24Industry P95: 0.23Peers compared: 194
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Altman Z-Score 10.27: safe zoneNotable
Altman Z-Score: 10.27
High structural barrier to entryNotable
Barrier to Entry: 0.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.07B, above the global median of $1.18BNotable
Market cap (USD): 5,066,637,924.736Global Median: 1,179,398,897.704
Levered free cash flow is $28.43M, above the global median of $19.19MNotable
Levered free cash flow (USD): 28,425,171.76Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Ipca Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Changchun High-Tech Industry Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Dyne Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dong-E-E-JiaoCo Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sk Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Edgewise Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables Growing
Coloplast A/S
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables Growing
United Airlines Holdings, Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables Growing